Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
BioSig Technologies Inc. (NASDAQ: BSGM) provides cutting-edge solutions in cardiac electrophysiology through its flagship PURE EP™ System. This page serves as the definitive source for official company news, including financial results, regulatory milestones, and clinical advancements.
Investors and healthcare professionals will find curated updates on product innovations, partnership announcements, and peer-reviewed research validating BioSig's signal processing technology. Key coverage areas: quarterly earnings reports, FDA clearances, hospital adoption metrics, and intellectual property developments.
All content undergoes strict verification to ensure alignment with SEC disclosure standards and medical device reporting regulations. Bookmark this page for real-time updates on BSGM's progress in enhancing cardiac ablation accuracy through advanced signal visualization technology.
BioSig Technologies (NASDAQ: BSGM) announced the appointment of Edwin Wang to its Advisory Board on March 27, 2023. Wang brings over 20 years of experience in private equity and venture capital, having founded Accretive Capital Partners LLC, which raised a top-quartile secondary direct investment fund. He previously directed the restructuring of a $1 billion venture capital portfolio at Asymmetry Capital LLC. His expertise is expected to enhance BioSig's capital markets strategy. BioSig's PURE EP™ System is gaining traction in the electrophysiology market, which is projected to reach $16 billion by 2028, aiming to improve patient outcomes and reduce healthcare costs.
FAQ
What is the current stock price of BioSig Technologies (BSGM)?
What is the market cap of BioSig Technologies (BSGM)?
